The DY12 monoclonal antibody specifically recognizes CD245 which is also known as p220/240. CD245 is variably expressed by T cells, B cells. NK cells, granulocytes, and platelets and more highly expressed on monocytes. CD245 expression can be upregulated on activated T cells, B cells, and NK cells. CD245 has been identified as Myosin 18A that is encoded by MYO18A (Myosin XVIIIA). Myosin 18A is also known as Myosin containing a PDZ domain (MysPDZ), Molecule associated with JAK3 N-terminus (MAJN), and Surfactant protein receptor SP-R2101 (SP-R2101). Myosin 18A is involved in intracellular transport processes and can also reportedly serve as a cell surface receptor for Surfactant Protein A (SP-A). The DY12 antibody reportedly immunoprecipitated long α (230 kDa) and short β (190 kDa) isoforms of Myosin 18A expressed by normal human lung extracts and by the YT2C2 NK cell line-further evidence suggested that the Myosin 18Aα isoform is expressed at the cell surface. CD245 stimulation mediated by bound and crosslinked DY12 antibody or the SP-A ligand can reportedly augment NK cell degranulation or IL-2-activated NK cell-mediated cytotoxicity against certain tumor target cells. Moreover, stimulation through CD245 can upregulate CD137/4-1BB expression on NK cells and promote NK cell-mediated cytotoxicity against CD137 Ligand-expressing target cells.
The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.